Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia 1Kidney Neoplasms 1Carcinoma, Renal Cell 1Breast Carcinoma In Situ 1Brain Neoplasms 1Advanced Cancer 1

Interventions

Nivolumab 11Ipilimumab 6linrodostat 4relatlimab 3Pemetrexed 2tislelizumab 1regorafenib 1ralimetinib 1p38 Mitogen-Activated Protein Kinases 1mirdametinib 1gedatolisib 1figitumumab 1efatutazone 1abemaciclib 1Vorinostat 1Tetanus Toxoid 1Tamoxifen 1Sunitinib 1Ranitidine 1Midazolam 1LY2603618 1LY2584702 1Irinotecan 1Gemcitabine 1Fulvestrant 1Dasatinib 1Cyclophosphamide 1Crizotinib 1Cetuximab 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced Cancer × Ranitidine × Clear all
NCT01287520 2019-02-25

A Study of LY2090314 in Patients With Advanced or Metastatic Cancer

Eli Lilly and Company

Phase 1 Completed
41 enrolled 28 charts

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡